Open-Label, Fixed-Sequence 3-Period Study to Determine the Effects of Repeated Oral Dosing of AQX-1125 on the Pharamacokinetics, Safety and Tolerability of a Combination Oral Contraceptive in Healthy Female Subjects

Trial Profile

Open-Label, Fixed-Sequence 3-Period Study to Determine the Effects of Repeated Oral Dosing of AQX-1125 on the Pharamacokinetics, Safety and Tolerability of a Combination Oral Contraceptive in Healthy Female Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Jun 2018

At a glance

  • Drugs Rosiptor (Primary) ; Oral contraceptives
  • Indications Allergic asthma; Interstitial cystitis
  • Focus Pharmacokinetics
  • Acronyms DDI-COC
  • Sponsors Aquinox Pharmaceuticals
  • Most Recent Events

    • 12 Jun 2018 Status changed from active, no longer recruiting to completed.
    • 29 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top